Shopping Cart
- Remove All
- Your shopping cart is currently empty
MPT0E028 is an orally active and selective inhibitor of HDAC [IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively] and demonstrates good anticancer activity, as it decreases the viability of B-cell lymphomas by inducing apoptosis, possesses potent direct Akt-targeting ability, and reduces Akt phosphorylation in B-cell lymphoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $766 | 6-8 weeks | |
50 mg | $995 | 6-8 weeks | |
100 mg | $1,740 | 6-8 weeks |
Description | MPT0E028 is an orally active and selective inhibitor of HDAC [IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2, and HDAC6, respectively] and demonstrates good anticancer activity, as it decreases the viability of B-cell lymphomas by inducing apoptosis, possesses potent direct Akt-targeting ability, and reduces Akt phosphorylation in B-cell lymphoma. |
Targets&IC50 | Akt:, HDAC2:106.2 nM, HDAC1:53.0 nM, HDAC8:2532.6 nM, HDAC6:29.5 nM |
Molecular Weight | 344.38 |
Formula | C17H16N2O4S |
Cas No. | 1338320-94-7 |
Relative Density. | 1.427 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.